Neoplasia: An International Journal for Oncology Research (Sep 2021)

Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer

  • Emanuela Guerra,
  • Marco Trerotola,
  • Valeria Relli,
  • Rossano Lattanzio,
  • Romina Tripaldi,
  • Giovanna Vacca,
  • Martina Ceci,
  • Khouloud Boujnah,
  • Valeria Garbo,
  • Antonino Moschella,
  • Romina Zappacosta,
  • Pasquale Simeone,
  • Robert de Lange,
  • Ulrich H. Weidle,
  • Maria Teresa Rotelli,
  • Arcangelo Picciariello,
  • Raffaella Depalo,
  • Patrizia Querzoli,
  • Massimo Pedriali,
  • Enzo Bianchini,
  • Domenico Angelucci,
  • Giuseppe Pizzicannella,
  • Carla Di Loreto,
  • Mauro Piantelli,
  • Laura Antolini,
  • Xiao-Feng Sun,
  • Donato F. Altomare,
  • Saverio Alberti

Journal volume & issue
Vol. 23, no. 9
pp. 898 – 911

Abstract

Read online

We recently reported that activation of Trop-2 through its cleavage at R87-T88 by ADAM10 underlies Trop-2–driven progression of colon cancer. However, the mechanism of action and pathological impact of Trop-2 in metastatic diffusion remain unexplored. Through searches for molecular determinants of cancer metastasis, we identified TROP2 as unique in its up-regulation across independent colon cancer metastasis models. Overexpression of wild-type Trop-2 in KM12SM human colon cancer cells increased liver metastasis rates in vivo in immunosuppressed mice. Metastatic growth was further enhanced by a tail-less, activated ΔcytoTrop-2 mutant, indicating the Trop-2 tail as a pivotal inhibitory signaling element. In primary tumors and metastases, transcriptome analysis showed no down-regulation of CDH1 by transcription factors for epithelial-to-mesenchymal transition, thus suggesting that the pro-metastatic activity of Trop-2 is through alternative mechanisms. Trop-2 can tightly interact with ADAM10. Here, Trop-2 bound E-cadherin and stimulated ADAM10-mediated proteolytic cleavage of E-cadherin intracellular domain. This induced detachment of E-cadherin from β-actin, and loss of cell-cell adhesion, acquisition of invasive capability, and membrane-driven activation of β-catenin signaling, which were further enhanced by the ΔcytoTrop-2 mutant. This Trop-2/E-cadherin/β-catenin program led to anti-apoptotic signaling, increased cell migration, and enhanced cancer-cell survival. In patients with colon cancer, activation of this Trop-2–centered program led to significantly reduced relapse-free and overall survival, indicating a major impact on progression to metastatic disease. Recently, the anti-Trop-2 mAb Sacituzumab govitecan-hziy was shown to be active against metastatic breast cancer. Our findings define the key relevance of Trop-2 as a target in metastatic colon cancer.

Keywords